Is IPSC or TYRA more profitable?

Tyra Biosciences' return on equity of -42.66% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% Tyra Biosciences N/A -42.66% -39.79%

Is PVLA or IPSC more profitable?

Century Therapeutics' return on equity of -49.89% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -56.87% -42.50% Century Therapeutics N/A -49.89% -37.42%

Does the media prefer PVLA or IPSC?

In the previous week, Century Therapeutics had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 6 mentions for Century Therapeutics and 4 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.80 beat Century Therapeutics' score of 0.26 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IPSC or SLS more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% SELLAS Life Sciences Group N/A -47.12% -42.63%

Does the media refer more to IPSC or SLS?

In the previous week, Century Therapeutics had 3 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Century Therapeutics and 3 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.62 beat Century Therapeutics' score of 0.26 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SION or IPSC more profitable?

Sionna Therapeutics' return on equity of -27.31% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -27.31% -25.88% Century Therapeutics N/A -49.89% -37.42%

Does the media prefer SION or IPSC?

In the previous week, Century Therapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 6 mentions for Century Therapeutics and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.93 beat Century Therapeutics' score of 0.26 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CMPS or IPSC more profitable?

Compass Pathways' return on equity of -31.07% beat Century Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -31.07% -11.40% Century Therapeutics N/A -49.89% -37.42%

Does the media refer more to CMPS or IPSC?

In the previous week, Century Therapeutics had 2 more articles in the media than Compass Pathways. MarketBeat recorded 6 mentions for Century Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.72 beat Century Therapeutics' score of 0.26 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Century Therapeutics (IPSC) Competitors

$2.12 -0.09 (-4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.00 (+0.24%)

As of 07:14 PM Eastern

Compare

IPSC vs. TYRA, PVLA, SLS, SION, and CMPS

Should you buy Century Therapeutics stock or one of its competitors? MarketBeat compares Century Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Century Therapeutics include Tyra Biosciences (TYRA), Palvella Therapeutics (PVLA), SELLAS Life Sciences Group (SLS), Sionna Therapeutics (SION), and Compass Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry.

How does Century Therapeutics compare to Tyra Biosciences?

Century Therapeutics (NASDAQ:IPSC) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Century Therapeutics presently has a consensus target price of $4.75, indicating a potential upside of 124.06%. Tyra Biosciences has a consensus target price of $46.00, indicating a potential upside of 80.96%. Given Century Therapeutics' higher probable upside, research analysts plainly believe Century Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Century Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.50	-$9.58M	-$1.14	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

In the previous week, Century Therapeutics had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Century Therapeutics and 1 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.87 beat Century Therapeutics' score of 0.26 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Century Therapeutics	Neutral
Tyra Biosciences	Very Positive

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Century Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Tyra Biosciences' return on equity of -42.66% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Tyra Biosciences	N/A	-42.66%	-39.79%

Summary

Century Therapeutics beats Tyra Biosciences on 8 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Century Therapeutics has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	34.23	-$41.72M	-$4.17	N/A
Century Therapeutics	$109.16M	3.50	-$9.58M	-$1.14	N/A

In the previous week, Century Therapeutics had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 6 mentions for Century Therapeutics and 4 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.80 beat Century Therapeutics' score of 0.26 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

Palvella Therapeutics presently has a consensus price target of $199.53, suggesting a potential upside of 95.26%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 124.06%. Given Century Therapeutics' higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics' return on equity of -49.89% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Century Therapeutics	N/A	-49.89%	-37.42%

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by insiders. Comparatively, 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Century Therapeutics beats Palvella Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Century Therapeutics compare to SELLAS Life Sciences Group?

Century Therapeutics (NASDAQ:IPSC) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Century Therapeutics presently has a consensus target price of $4.75, suggesting a potential upside of 124.06%. SELLAS Life Sciences Group has a consensus target price of $10.00, suggesting a potential upside of 39.86%. Given Century Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Century Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Century Therapeutics had 3 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Century Therapeutics and 3 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.62 beat Century Therapeutics' score of 0.26 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Century Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

Century Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.50	-$9.58M	-$1.14	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

SELLAS Life Sciences Group's return on equity of -47.12% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

Summary

Century Therapeutics beats SELLAS Life Sciences Group on 10 of the 14 factors compared between the two stocks.

How does Century Therapeutics compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Century Therapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 6 mentions for Century Therapeutics and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.93 beat Century Therapeutics' score of 0.26 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.2% of Century Therapeutics shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Century Therapeutics has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Century Therapeutics	$109.16M	3.50	-$9.58M	-$1.14	N/A

Sionna Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Sionna Therapeutics presently has a consensus price target of $53.22, suggesting a potential upside of 56.40%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 124.06%. Given Century Therapeutics' higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Sionna Therapeutics' return on equity of -27.31% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Century Therapeutics	N/A	-49.89%	-37.42%

Summary

Century Therapeutics beats Sionna Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Century Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Century Therapeutics	$109.16M	3.50	-$9.58M	-$1.14	N/A

Compass Pathways' return on equity of -31.07% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Century Therapeutics	N/A	-49.89%	-37.42%

Compass Pathways has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

In the previous week, Century Therapeutics had 2 more articles in the media than Compass Pathways. MarketBeat recorded 6 mentions for Century Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.72 beat Century Therapeutics' score of 0.26 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways presently has a consensus price target of $21.36, suggesting a potential upside of 93.69%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 124.06%. Given Century Therapeutics' higher probable upside, analysts clearly believe Century Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Compass Pathways beats Century Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPSC vs. The Competition

Export

Metric	Century Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$398.58M	$2.96B	$6.50B	$11.95B
Dividend Yield	N/A	1.70%	2.67%	5.61%
P/E Ratio	-1.86	17.80	24.65	23.63
Price / Sales	3.50	289.23	498.98	103.49
Price / Cash	166.17	56.16	43.05	54.72
Price / Book	1.16	3.88	10.43	6.70
Net Income	-$9.58M	$75.85M	$3.56B	$337.26M
7 Day Performance	2.42%	-1.87%	-1.39%	-1.41%
1 Month Performance	-7.42%	-6.20%	0.86%	1.15%
1 Year Performance	233.96%	12.60%	19.42%	22.61%

Century Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPSC Century Therapeutics	2.4156 of 5 stars	$2.12 -4.1%	$4.75 +124.1%	+252.6%	$398.58M	$109.16M	N/A	170	News Coverage
TYRA Tyra Biosciences	2.8693 of 5 stars	$25.40 -5.0%	$46.50 +83.0%	+152.8%	$1.51B	N/A	N/A	20	Positive News Analyst Forecast
PVLA Palvella Therapeutics	2.4497 of 5 stars	$103.93 -1.3%	$199.53 +92.0%	+291.9%	$1.49B	N/A	N/A	N/A	Gap Up
SLS SELLAS Life Sciences Group	1.6914 of 5 stars	$7.53 -5.7%	$10.00 +32.9%	+389.2%	$1.49B	N/A	N/A	10
SION Sionna Therapeutics	3.0906 of 5 stars	$32.98 -1.6%	$53.22 +61.4%	+104.7%	$1.49B	N/A	N/A	35	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPSC) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Century Therapeutics (IPSC) Competitors

IPSC vs. TYRA, PVLA, SLS, SION, and CMPS

How does Century Therapeutics compare to Tyra Biosciences?

Summary

How does Century Therapeutics compare to Palvella Therapeutics?

Summary

How does Century Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does Century Therapeutics compare to Sionna Therapeutics?

Summary

How does Century Therapeutics compare to Compass Pathways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Century Therapeutics (IPSC) Competitors

IPSC vs. TYRA, PVLA, SLS, SION, and CMPS

How does Century Therapeutics compare to Tyra Biosciences?

Do analysts recommend IPSC or TYRA?

Which has better earnings & valuation, IPSC or TYRA?

Does the media favor IPSC or TYRA?

Do institutionals & insiders believe in IPSC or TYRA?

Which has more risk and volatility, IPSC or TYRA?

Is IPSC or TYRA more profitable?

Summary

How does Century Therapeutics compare to Palvella Therapeutics?

Which has preferable earnings and valuation, PVLA or IPSC?

Does the media prefer PVLA or IPSC?

Which has more risk and volatility, PVLA or IPSC?

Do analysts recommend PVLA or IPSC?

Is PVLA or IPSC more profitable?

Do insiders & institutionals hold more shares of PVLA or IPSC?

Summary

How does Century Therapeutics compare to SELLAS Life Sciences Group?

Do analysts recommend IPSC or SLS?

Does the media refer more to IPSC or SLS?

Do insiders and institutionals hold more shares of IPSC or SLS?

Which has more risk & volatility, IPSC or SLS?

Which has higher valuation and earnings, IPSC or SLS?

Is IPSC or SLS more profitable?

Summary

How does Century Therapeutics compare to Sionna Therapeutics?

Does the media prefer SION or IPSC?

Do institutionals & insiders hold more shares of SION or IPSC?

Which has stronger earnings and valuation, SION or IPSC?

Which has more volatility and risk, SION or IPSC?

Do analysts rate SION or IPSC?

Is SION or IPSC more profitable?

Summary

How does Century Therapeutics compare to Compass Pathways?

Which has better valuation & earnings, CMPS or IPSC?

Is CMPS or IPSC more profitable?

Which has more volatility and risk, CMPS or IPSC?

Does the media refer more to CMPS or IPSC?

Do analysts prefer CMPS or IPSC?

Do institutionals and insiders hold more shares of CMPS or IPSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools